Aussie cycling star Ewan announces shock retirement
Ewan, who recorded 65 career victories including 11 across the Tour de France, Giro and Vuelta, had begun his first season with Ineos in good shape.
The combative sprint specialist had won the first stage of the Settimana Internazionale di Coppi e Bartali and then the second stage of the Tour of the Basque Country in April.
However, on Tuesday he brought down the curtain on his 11 year career.
"After much thought, I've decided to retire from professional cycling, effective immediately," he said in a statement on the British team's website.
"The last few years haven't been easy but in 2025 I found something again -— not just legs, but belief -— thanks to the INEOS Grenadiers.
"But the truth is that even when I crossed the line first, that feeling —- the one you chase for years — faded quicker than it used to."
Ewan, who would likely have been in the team for this year's Tour de France, alluded to bad experiences with his past two teams.
He left Lotto at the end of 2023, after five years, following a disagreement with new team chief Stephane Heulot and stayed for just a season with Aussie outfit Team Jayco AlUla.
"My experiences of the past two seasons, in particular the second half of 2024, has taken a significant toll on my relationship with the sport."
He added that he was leaving the sport content that "I've accomplished more than I ever imagined possible".
INEOS bade him a fond farewell.
pi/bsp
© 2025 AFP
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
France 24
a day ago
- France 24
Carapaz knocked out of Tour de France with stomach bug
"Last week, he began experiencing abdominal pain and a high fever," said his team EF on their website. "(Doctors) have advised against long-haul travel and competition at this time. As a result, Richard will not take part in this year's Tour de France." Carapaz finished third in the Giro d'Italia earlier in June and would have led the EF Pro Cycling team in the Tour, which starts on July 5. "We're all gutted for Richard," said Jonathan Vaughters, the EF chief. "He came out of the Giro with amazing form. "He sacrificed a lot to get to that level, so the timing really couldn't be worse. We know how much the Tour means to him, so to lose him this close to the race is a real blow." Carapaz, the 2020 Olympic champion and 2019 Giro winner, won the climbing and combativity prizes in last year's Tour de France. The team said that the 32-year-old "will take a few weeks off to let his body fully recover" and then shift his focus to the least prestigious of the Grand Tours starting on August 23. "His goal? Win the Vuelta a Espana," said the team.
France 24
3 days ago
- France 24
UAE name powerful team to support Pogacar in Tour de France
The 26-year-old Slovenian has ridden the three-week Tour five times, winning three and finishing second to Jonas Vingegaard in 2022 and 2023. "It's hard to believe it's already my sixth Tour de France, time flies," he said in the team press release. He started the season by taking the UAE Tour, then won four one-day races, including Liege-Bastogne-Liege, finishing on the podium in three others. He ended his Tour preparation by winning the penultimate warm-up event, the eight-day Criterium du Dauphine. "I'm lucky to have had close to the perfect preparation this year — everything has gone really smoothly," said Pogacar. He will be backed by five of the team-mates who helped him to victory in the Dauphine -- Marc Soler, Nils Politt, Pavel Sivakov, Tim Wellens and Jhonatan Narvaez. Reflecting the depth of the UAE squad, they will be joined by Adam Yates and Joao Almeida, who both finished in the top six in last year's Tour de France. In Pogacar's absence, Almeida won the final Tour warm-up, the Tour of Switzerland, for his third stage-race victory this season. "The vibes in the team are amazing right now, and that gives me a lot of confidence," said Pogacar. Team UAE Tour de France squad: Joao Almeida (POR), Jhonatan Narvaez (ECU), Tadej Pogacar (SLO), Nils Politt (GER), Pavel Sivakov (FRA), Marc Soler (ESP), Tim Wellens (BEL), Adam Yates (GBR).
Euronews
4 days ago
- Euronews
Euronews Tech Talks Podcast
In January 2013, the world of sports was shaken by an interview conducted by the American powerhouse broadcaster Oprah Winfrey with the cycling champion Lance Armstrong. Armstrong, who had won seven consecutive Tour de France titles from 1999 to 2005, publicly admitted using banned substances to enhance his performance during official competitions, confirming long-standing suspicions that had followed him for years. Armstrong left a mark on the history of doping. As a cancer survivor, his achievements represented a sign of hope and resilience, and what happened next was described by many as the fall of a hero. It goes without saying that Armstrong's case was neither the first nor the last doping scandal. But why exactly do athletes resort to doping? What substances do they use, and why are they so difficult to detect? Euronews Tech Talks set out to better understand doping with Andrea Petróczi, professor of public health at Kingston University in the United Kingdom. She also regularly provides consultancy to the World Anti-Doping Agency. What is doping? Petróczi said that researchers have not yet agreed on the exact definition of doping. However, she said the World Anti-Doping Code provides clear rules for athletes to understand what doping is and who can be accused of it. 'Doping is defined as the occurrence of one or more of the anti-doping rules violations set forth in Article 2.1 through Article 2.11 of the Code,' the Code states. There are 11 anti-doping rule violations, which include not only the use of substances but also the attempted use of these agents. Moreover, even if an athlete did not intend to cheat, they can still face sanctions if a banned substance is found in their system. Some of these rules apply not only to the athletes but also to their support personnel. According to the Code, any substance or method that meets two out of three criteria is classified as prohibited. These criteria are: evidence that the substance enhances performance, evidence that it poses a health risk, and evidence that it goes against the spirit of sport. Based on these criteria, 'a substance doesn't necessarily have to be performance-enhancing to be prohibited". Petróczi said. "If it's deemed risky to the athlete's health and against the spirit of sport, then it can be added to the list,' she added. The most well-known doping substances are EPO and anabolic steroids. EPO, or erythropoietin, is a hormone produced by the kidneys to stimulate the production of red blood cells, helping transport oxygen to the muscles. It is commonly used in sports like marathons or cycling, as it boosts endurance. By contrast, anabolic steroids are synthetic compounds similar to testosterone that promote muscle growth, and they are used in sprint or weight lifting competitions. Caffeine was also considered a prohibited substance and was reintroduced only in 2004. Although now allowed, it has since then been on the World Anti-Doping Agency's monitoring programme. Is doping too difficult to detect? Andrea Petróczi stated that 'doping is not difficult to detect because the detection limit is low'. However, she acknowledged the major challenges in detecting doping and argued that they depend on multiple factors, including whether the anti-doping authorities know or not about the substance being used and the timing of the doping test. For instance, Petróczi explained that microdoses of prohibited substances are complicated to identify, not because of their small amount, but because they remain in the body for only a short time. This makes them hard to identify unless testing occurs within a narrow window. She also pointed out that given the advancements in equipment, diets and training, it is more difficult to understand the limit between excellent preparation and the use of doping substances. 'In the future, what poses a challenge for anti-doping is not a new drug necessarily," Petróczi said. "But the combination of the existing drugs with data science, with specialised training, with equipment, each providing a marginal gain, but in combination, the synergistic effect,' she added.
